Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xuan Ge
Institutions:
City Of Hope National Medical Center,
City of Hope
Observed institutions:
City Of Hope National Medical Center,
City of Hope
ORCID:
0000-0002-4703-4238
Observed ORCID:
0000-0002-4703-4238
OpenAlex ID:
A5013275278
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
2023
·
Colt A. Egelston
, Weihua Guo
, et al.
·
Cancer Immunology Immunotherapy
·
27
PDF
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
2022
·
Xuan Ge
, Susan E. Yost
, et al.
·
Cancers
·
13
PDF
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
2023
·
Xuan Ge
, Carolyn E Behrendt
, et al.
·
The Oncologist
·
8
PDF
Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer.
2022
·
Xuan Ge
, Carolyn E. Behrendt
, et al.
·
Journal of Clinical Oncology
·
2
Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer.
2022
·
Yuan Yuan
, Xuan Ge
, et al.
·
Journal of Clinical Oncology
·
1
Abstract OT2-08-03: Immunogenicity of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple negative breast cancer
2023
·
Colt A. Egelston
, Weihua Guo
, et al.
·
Cancer Research
Phase I study combining pembrolizumab and aromatase inhibitor in patients with metastatic hormone receptor–positive breast cancer.
2022
·
Xuan Ge
, Susan Elaine Yost
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
7
Citation count:
51
H-index:
3
I10-index:
2
Year
Topic
Type